Nu-Med Plus (NUMD) Cash from Financing Activities (2012 - 2025)

Nu-Med Plus' (NUMD) quarterly Cash from Financing Activities came in at $33767.0 in Q4 2025, up 12.56% quarter-over-quarter from $30000.0 in Q1 2021.

Nu-Med Plus (NUMD) Cash from Financing Activities (2012 - 2025) Analysis & Trends

Nu-Med Plus has disclosed Cash from Financing Activities across 11 years of filings, most recently posting $33767.0 for Q4 2025.

Cash from Financing Activities for Q4 2025 came in at $33767.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $33767.0 (changed N/A YoY), and the FY2025 annual result was $46267.0, changed N/A from the prior year.
Cash from Financing Activities came in at $33767.0 for Q4 2025 at Nu-Med Plus, up from $30000.0 in the prior quarter.
In the past five years, Cash from Financing Activities ranged from a high of $33767.0 in Q4 2025 to a low of $30000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Financing Activities (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	17.31 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	-1.51 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	-2.09 Bn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	-260.00 Mn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	-451.20 Mn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	21.00 Mn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	-26.93 Mn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-25.00 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	-97.90 Mn
10	Nu-Med Plus	-	-	-	33,767.00

Download Data